San Diego, CA – March 14, 2016 – GlySens Incorporated today completed the successful re-implantation of the Eclipse™ ICGM® Sensor in a sixth human subject participating in the Function of Implanted Glucose Sensor 2 (FIGS-2) trial [ NCT02345967] for people with diabetes in the United States. The FIGS-2 study is a multi-center, long- term assessment of the Eclipse ICGM Sensor. Re-implantation of the sixth participant is a crucial step in the sensor development as participants enroll in a second 12-month, in-vivo trial period. “These new data will support our ongoing signal processing assessments as well as an overall assessment of the long term use-case of our implantable technology,” said Joseph Lucisano, PhD, the Company’s founder and CTO. The primary objective of the FIGS-2 trial is to verify safety and assess tolerance of a long-term, implanted glucose monitoring sensor. The study will also provide data to characterize the response properties and calibration of the implanted sensor and determine if such properties vary with implant duration. The Figs 2 trial is no longer enrolling participants but remains ongoing for data collection.